Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia

Saudi Medical Journal

Volumn 26, Issue 6, 2005, Pages 956-959

  Kader, Abdulrahman A ^a   Angamuthu, Kumar ^a  

^a Almana General Hospital   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BALLOON CATHETER; ENTEROBACTER; ENZYME SYNTHESIS; ESCHERICHIA COLI; GENERAL HOSPITAL; GRAM NEGATIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; INDWELLING CATHETER; KLEBSIELLA PNEUMONIAE; LONG TERM CARE; MAJOR CLINICAL STUDY; NONHUMAN; OUTPATIENT; PREVALENCE; PSEUDOMONAS AERUGINOSA; SAUDI ARABIA; URINALYSIS; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFTAZIDIME; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; HUMANS; KLEBSIELLA PNEUMONIAE; URINARY TRACT INFECTIONS;

EID: 22544439657     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
2. Wong-Beringer A. therapeutic challenges associated with extended-spectrum β -lactamase-producing Esherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001; 21: 583-592.
3. Sirot D. Extended-spectrum plasmid mediated β-lactamases. J Antimicrob Chemother 1995; 36 (Suppl A): 19-34.
4. Rice LE. Successful interventions for gram-negative resistance to extended-spectrum β-lactam antibiotics. Pharmacotherapy 1999; 19 (8 pt 2): S120-128.
5. Paterson DL, Ko WC, Mohapatra S, Von Gottberg A. Klebsiella pneumoniae bacteremia: impact of extended-spectrum β-lactamase (ESBL) production in a global study of 216 patients [abstr]. In: Program and abstracts of the 37th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 1997: 328.
6. Steward CD, Rasheed JK, Hubert SK, Biddle JW, Raney PM, Anderson GJ, et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum β-lactamase detection methods. J Clin Microbiol 2001; 39: 2864-2872.
7. Livermore DM. β-Lactamase-mediated resistance and opportunities for its control. J Animicrob Chemother 1998; 41 (Suppl D): 25-41.
8. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. In-vitro susceptibility and clinical outcome of bacteraemia due to ESBL producing Klebsiella pneumoniae. 36th Annual Meeting of the Infectious Diseases Society of America, Denver, Colarado. Abstract # 188 Sa.
9. Cowan SF, Steel KJ. Manual for identification of medical bacteria. 3rd ed. Cambridge: Cambridge University Press; 1993. p. 140-143.
10. Performance standards for antimicrobial susceptibility testing. Tenth informational supplement. NCCLS document M100-S10 (M2). National Committee for Clinical Laboratory Standards, 2000.
11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
12. Jones RN, Kugler KC, Pfaller MA, Winokur PL. Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY antimicrobial surveillance program, 1997 SENTRY Surveillance Group. Diagn Microbiol Infect Dis 1999; 35: 55-63.
13. Babypadmini S, Appalaraju B. Extended-spectrum β-lactamases in urinary isolates of Esherichia coli and Klebsiella pneumoniae- Prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004; 22: 172-174.
14. 'Agata EM, Venkataraman L, DeGirolami P, Burke P, Eliopoulos GM, Karchmer AW, et al. Colonization with broad-spectrum cephalosporin-resistant gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med 1999; 27: 1090-1095.
15. Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY, et al. Ceftazidime resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case control and molecular epidemiologic investigation. J Infect Dis 1996; 174: 529-536.
16. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamases-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact on resistance of outcomes. Clin Infect Dis 2001; 32: 1162-1171.
17. Nicolle LE, Bentley D, Garibaldi R, Neuhaus EG, Smith PW. SHEA Position Paper: Antimicrobial Use in Long-Term Care Facilities. Infect Control Hosp Epidemiol 2000; 21: 537-545.
18. Melloh J. Urosepsis. In: Ham RJ, Sloan PD, editors Primary Care Geriatrics. 2nd ed. St Louis: Mosby Year Book; 1992. p. 617-618.
19. Jean S, Teng L, Hsuch P, Ho S, Luh K. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant gram-negative bacteria in a Taiwanese university hospital. J Animicrob Chemother 2002; 49: 69-76.
20. Burgess DS, Hall RG, Lewis JS, Jorgensen JH, Patterson JE. Clinical and Microbiological Analysis of a Hospital's Extended-spectrum Beta-lactamase-Producing Isolates Over a 2-Year period. Pharmacotherapy 2003; 23: 1232-1237.